SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs - Quaterly Results

07 Feb 2023 Evaluate
The Sales for the quarter ended December 2022 of Rs. 171.32 million declined by -39.21% from Rs. 281.82 millions.The Net Loss for the quarter ended December 2022 is Rs. -102.14 millions as compared to Net Profit of Rs. 56.79 millions of corresponding quarter ended December 2021The Operating Profit of the company witnessed a decrease to 33.33 millions from 125.96 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 171.32 281.82 -39.21 611.37 1366.66 -55.27 1643.49 622.63 163.96
Other Income 11.14 6.73 65.53 28.37 20.60 37.72 27.20 22.10 23.08
PBIDT 33.33 125.96 -73.54 157.07 879.96 -82.15 1002.19 166.35 502.46
Interest 30.42 45.95 -33.80 87.57 170.12 -48.52 199.21 255.53 -22.04
PBDT -66.06 81.79 -180.77 -0.85 691.19 -100.12 756.30 -103.47 -830.94
Depreciation 33.25 21.18 56.99 101.94 62.58 62.90 153.89 80.50 91.17
PBT -99.31 60.61 -263.85 -102.79 628.61 -116.35 602.41 -183.97 -427.45
TAX 2.83 3.82 -25.92 0.04 77.25 -99.95 203.38 -39.36 -616.72
Deferred Tax -2.72 3.82 -171.20 -5.51 77.25 -107.13 203.38 -39.36 -616.72
PAT -102.14 56.79 -279.86 -102.83 551.36 -118.65 399.03 -144.61 -375.94
Equity 286.90 286.90 0.00 286.90 286.90 0.00 286.90 286.90 0.00
PBIDTM(%) 19.45 44.70 -56.47 25.69 64.39 -60.10 60.98 26.72 128.24

Lyka Labs Share Price

58.16 0.56 (0.97%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×